The Long March to a Cure for Pulmonary Hypertension.
作者信息
Humbert Marc
出版信息
JACC Asia. 2022 May 17;2(3):215-217. doi: 10.1016/j.jacasi.2022.04.003. eCollection 2022 Jun.
Abstract
摘要
相似文献
1
The Long March to a Cure for Pulmonary Hypertension.治愈肺动脉高压的长征之路。
JACC Asia. 2022 May 17;2(3):215-217. doi: 10.1016/j.jacasi.2022.04.003. eCollection 2022 Jun.
2
How does pulmonary endarterectomy cure CTEPH: A clue to cure PAH?肺动脉内膜剥脱术如何治愈慢性血栓栓塞性肺动脉高压：治愈肺动脉高压的线索？
Am J Physiol Lung Cell Mol Physiol. 2016 Oct;311(4):L766-L769. doi: 10.1152/ajplung.00288.2016. Epub 2016 Sep 2.
3
Chronic thromboembolic pulmonary hypertension in Australia and New Zealand: An analysis of the PHSANZ registry.澳大利亚和新西兰的慢性血栓栓塞性肺动脉高压：PHSANZ 登记处分析。
Respirology. 2021 Dec;26(12):1171-1180. doi: 10.1111/resp.14162. Epub 2021 Oct 5.
4
Diagnosis and treatment of pulmonary artery hypertension.
Curr Opin Pediatr. 1996 Oct;8(5):512-9. doi: 10.1097/00008480-199610000-00016.
5
Bayesian Spatial Survival Analysis of Duration to Cure among New Smear-Positive Pulmonary Tuberculosis (PTB) Patients in Iran, during 2011-2018.伊朗新涂阳肺结核（PTB）患者治愈时间的贝叶斯空间生存分析，2011-2018 年。
Int J Environ Res Public Health. 2020 Dec 23;18(1):54. doi: 10.3390/ijerph18010054.
6
[Causes and management of respiratory complication after liver transplantation].[肝移植术后呼吸并发症的病因及处理]
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2004 Mar;33(2):170-3. doi: 10.3785/j.issn.1008-9292.2004.02.018.
7
New developments in pulmonary hypertension/pulmonary arterial hypertension. Proceedings of Pulmonary Hypertension UP2DATE 2008 - post Dana Point. March 14-15, 2008. Munich, Germany.
Dtsch Med Wochenschr. 2008 Oct;133 Suppl 6:S165-218.
8
Valve patch technique for repair of ventricular septal defect: long-term results.瓣膜修补术治疗室间隔缺损：长期结果。
Asian Cardiovasc Thorac Ann. 2021 Mar;29(3):161-164. doi: 10.1177/0218492320962923. Epub 2020 Sep 26.
9
Pulmonary arterial hypertension: Basic knowledge for clinicians.肺动脉高压：临床医生的基础知识。
Arch Cardiovasc Dis. 2016 Oct;109(10):550-561. doi: 10.1016/j.acvd.2016.03.004. Epub 2016 Aug 29.
10
MicroRNAs and mesenchymal stem cells: hope for pulmonary hypertension.微小RNA与间充质干细胞：肺动脉高压的希望
Rev Bras Cir Cardiovasc. 2015 Jul-Sep;30(3):380-5. doi: 10.5935/1678-9741.20150033.
本文引用的文献
1
Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?积极降低后负荷以改善右心室：肺动脉高压的新药物治疗靶点？
Am J Respir Crit Care Med. 2022 Apr 1;205(7):751-760. doi: 10.1164/rccm.202109-2079PP.
2
External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry.法国肺动脉高压注册研究中一种改良的四分层风险评估评分的外部验证。
Eur Respir J. 2022 Jun 30;59(6). doi: 10.1183/13993003.02419-2021. Print 2022 Jun.
3
COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension.COMPERA 2.0：一种改良的肺动脉高压四层风险评估模型。
Eur Respir J. 2022 Jul 7;60(1). doi: 10.1183/13993003.02311-2021. Print 2022 Jul.
4
Clinical features and survival in Takayasu's arteritis-associated pulmonary hypertension: a nationwide study.大动脉炎相关性肺动脉高压的临床特征和生存情况：一项全国性研究。
Eur Heart J. 2021 Nov 7;42(42):4298-4305. doi: 10.1093/eurheartj/ehab599.
5
Pulmonary vascular resistance predicts mortality in patients with pulmonary hypertension associated with interstitial lung disease: results from the COMPERA registry.肺血管阻力可预测与间质性肺疾病相关的肺动脉高压患者的死亡率：来自COMPERA注册研究的结果
Eur Respir J. 2021 Aug 26;58(2). doi: 10.1183/13993003.01483-2021. Print 2021 Aug.
6
Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension.初始治疗策略与肺动脉高压长期生存的关系。
Am J Respir Crit Care Med. 2021 Oct 1;204(7):842-854. doi: 10.1164/rccm.202009-3698OC.
7
Elevated pulmonary vascular resistance predicts mortality in COPD patients.肺血管阻力升高预示慢性阻塞性肺疾病患者的死亡率。
Eur Respir J. 2021 Aug 26;58(2). doi: 10.1183/13993003.00944-2021. Print 2021 Aug.
8
Sotatercept for the Treatment of Pulmonary Arterial Hypertension.索他拉特塞治疗肺动脉高压。
N Engl J Med. 2021 Apr 1;384(13):1204-1215. doi: 10.1056/NEJMoa2024277.
9
An endothelial activin A-bone morphogenetic protein receptor type 2 link is overdriven in pulmonary hypertension.肺高血压中内皮细胞激活素 A-骨形态发生蛋白受体 2 联系被过度驱动。
Nat Commun. 2021 Mar 19;12(1):1720. doi: 10.1038/s41467-021-21961-3.
10
Multi-Institutional Prospective Cohort Study of Patients With Pulmonary Hypertension Associated With Respiratory Diseases.多机构前瞻性队列研究：患有与呼吸系统疾病相关的肺动脉高压的患者。
Circ J. 2021 Mar 25;85(4):333-342. doi: 10.1253/circj.CJ-20-0939. Epub 2021 Feb 2.
Zotero 插件